Securities Code: 300813
Securities Abbreviation: Tailin Bio
Announcement No.: 2026-046
Zhejiang Tailin Bio-technology Co., Ltd.
Announcement of Resolutions of the 14th Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The 14th Meeting of the Fourth Board of Directors of Zhejiang Tailin Bio-technology Co., Ltd. (hereinafter referred to as the "Company") was held on July 1, 2026, at the Company's meeting room through on-site and teleconference methods. The notice and meeting materials for this meeting were issued on June 30, 2026, through telephone, written delivery, and other forms. All directors unanimously agreed to waive the notice period for this meeting. Seven directors were required to attend, and seven directors actually attended. The meeting was convened and presided over by Mr. Ye Dalin, and senior management personnel of the Company were present. The convening of this meeting complies with the requirements of the "Company Law of the People's Republic of China," the "Articles of Association," and relevant laws and administrative regulations. The meeting was legal and valid.
II. Deliberation of Board Meeting Matters
After deliberation by the attending directors, the meeting passed the following proposals:
(I) Proposal on the "Proposal on the Plan for the Company to Issue Convertible Corporate Bonds to Unspecified Targets (Revised Draft)" was considered and approved.
In accordance with the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Administrative Measures for the Registration of Securities Issuance by Listed Companies," the "Measures for the Administration of Convertible Corporate Bonds," and other laws, regulations, and normative documents, as well as the authorization granted by the Company's 2025 Annual Shareholders' Meeting to the Board of Directors, the Company has adjusted the terms such as the use of proceeds for the current issuance of convertible corporate bonds to unspecified targets based on the actual situation. The specific details are as follows:
- Use of Proceeds from This Issuance
Before Adjustment:
The total amount of proceeds from the Company's issuance of convertible corporate bonds to unspecified targets shall not exceed RMB 230,000,000 (inclusive). After deducting issuance expenses, the proceeds will be used for the following projects: